Tags

Type your tag names separated by a space and hit enter

Comparison of treatment response, survival and safety between drug-eluting bead transarterial chemoembolization with CalliSpheres® microspheres versus conventional transarterial chemoembolization in treating hepatocellular carcinoma.
J BUON. 2019 May-Jun; 24(3):1150-1166.JB

Abstract

PURPOSE

To compare the efficacy and safety between drug-eluting bead (DEB) transarterial chemoembolization (TACE) with CalliSpheres® microspheres (CSM) and conventional TACE (cTACE) in hepatocellular carcinoma (HCC) patients, and to explore the predictive factors for treatment response and survival.

METHODS

89 HCC patients receiving DEB-TACE with CSM or cTACE were consecutively recruited in this cohort study. Treatment response was assessed at month 1 (M1)/M3/M6. Progression free survival (PFS) and overall survival (OS) were calculated. Liver function indexes were measured at M1 and adverse events occurred during operation and hospitalization were recorded.

RESULTS

Higher complete response (CR) rate and objective response rate (ORR) at M1/M3 in DEB-TACE group were found compared to cTACE group, and no difference of PFS and OS was noted between the two groups. Multivariate analysis of ORR, DFS and OS disclosed that multifocal disease, ALT≥1upper limit of normal (ULN) and ALP≥1ULN independently predicted lower ORR, while bilobar tumor location and abnormal CA19.9 level were independent predictive factors for unfavorable PFS. As for liver function, there was no difference of all liver function indexes changes (M1-M0) between the two groups. Moreover, DEB-TACE group displayed more frequent pain during treatment, and more frequent pain and fever during hospitalization compared to cTACE group.

CONCLUSIONS

The short-term CR and ORR of DEB-TACE treatment with CSM are better, while OS, DFS and safety were equivalent compared to cTACE in treating HCC patients.

Authors+Show Affiliations

Department of Interventional Radiology, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, Guangxi, China.No affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

31424674

Citation

Zhao, Chang, and Shenglin Pei Zuyi Chen Yilong Ma. "Comparison of Treatment Response, Survival and Safety Between Drug-eluting Bead Transarterial Chemoembolization With CalliSpheres® Microspheres Versus Conventional Transarterial Chemoembolization in Treating Hepatocellular Carcinoma." Journal of B.U.ON. : Official Journal of the Balkan Union of Oncology, vol. 24, no. 3, 2019, pp. 1150-1166.
Zhao C, Ma SPZCY. Comparison of treatment response, survival and safety between drug-eluting bead transarterial chemoembolization with CalliSpheres® microspheres versus conventional transarterial chemoembolization in treating hepatocellular carcinoma. J BUON. 2019;24(3):1150-1166.
Zhao, C., & Ma, S. P. Z. C. Y. (2019). Comparison of treatment response, survival and safety between drug-eluting bead transarterial chemoembolization with CalliSpheres® microspheres versus conventional transarterial chemoembolization in treating hepatocellular carcinoma. Journal of B.U.ON. : Official Journal of the Balkan Union of Oncology, 24(3), 1150-1166.
Zhao C, Ma SPZCY. Comparison of Treatment Response, Survival and Safety Between Drug-eluting Bead Transarterial Chemoembolization With CalliSpheres® Microspheres Versus Conventional Transarterial Chemoembolization in Treating Hepatocellular Carcinoma. J BUON. 2019 May-Jun;24(3):1150-1166. PubMed PMID: 31424674.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Comparison of treatment response, survival and safety between drug-eluting bead transarterial chemoembolization with CalliSpheres® microspheres versus conventional transarterial chemoembolization in treating hepatocellular carcinoma. AU - Zhao,Chang, AU - Ma,Shenglin Pei Zuyi Chen Yilong, PY - 2019/8/20/entrez PY - 2019/8/20/pubmed PY - 2020/3/18/medline SP - 1150 EP - 1166 JF - Journal of B.U.ON. : official journal of the Balkan Union of Oncology JO - J BUON VL - 24 IS - 3 N2 - PURPOSE: To compare the efficacy and safety between drug-eluting bead (DEB) transarterial chemoembolization (TACE) with CalliSpheres® microspheres (CSM) and conventional TACE (cTACE) in hepatocellular carcinoma (HCC) patients, and to explore the predictive factors for treatment response and survival. METHODS: 89 HCC patients receiving DEB-TACE with CSM or cTACE were consecutively recruited in this cohort study. Treatment response was assessed at month 1 (M1)/M3/M6. Progression free survival (PFS) and overall survival (OS) were calculated. Liver function indexes were measured at M1 and adverse events occurred during operation and hospitalization were recorded. RESULTS: Higher complete response (CR) rate and objective response rate (ORR) at M1/M3 in DEB-TACE group were found compared to cTACE group, and no difference of PFS and OS was noted between the two groups. Multivariate analysis of ORR, DFS and OS disclosed that multifocal disease, ALT≥1upper limit of normal (ULN) and ALP≥1ULN independently predicted lower ORR, while bilobar tumor location and abnormal CA19.9 level were independent predictive factors for unfavorable PFS. As for liver function, there was no difference of all liver function indexes changes (M1-M0) between the two groups. Moreover, DEB-TACE group displayed more frequent pain during treatment, and more frequent pain and fever during hospitalization compared to cTACE group. CONCLUSIONS: The short-term CR and ORR of DEB-TACE treatment with CSM are better, while OS, DFS and safety were equivalent compared to cTACE in treating HCC patients. SN - 2241-6293 UR - https://www.unboundmedicine.com/medline/citation/31424674/Comparison_of_treatment_response_survival_and_safety_between_drug_eluting_bead_transarterial_chemoembolization_with_CalliSpheres®_microspheres_versus_conventional_transarterial_chemoembolization_in_treating_hepatocellular_carcinoma_ L2 - https://www.jbuon.com/archive/24-3-1150.pdf DB - PRIME DP - Unbound Medicine ER -